Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors.
Mullamitha SA, Ton NC, Parker GJ, Jackson A, Julyan PJ, Roberts C, Buonaccorsi GA, Watson Y, Davies K, Cheung S, Hope L, Valle JW, Radford JA, Lawrance J, Saunders MP, Munteanu MC, Nakada MT, Nemeth JA, Davis HM, Jiao Q, Prabhakar U, Lang Z, Corringham RE, Beckman RA, Jayson GC. Mullamitha SA, et al. Among authors: watson y. Clin Cancer Res. 2007 Apr 1;13(7):2128-35. doi: 10.1158/1078-0432.CCR-06-2779. Clin Cancer Res. 2007. PMID: 17404096 Clinical Trial.
Phase I evaluation of CDP791, a PEGylated di-Fab' conjugate that binds vascular endothelial growth factor receptor 2.
Ton NC, Parker GJ, Jackson A, Mullamitha S, Buonaccorsi GA, Roberts C, Watson Y, Davies K, Cheung S, Hope L, Power F, Lawrance J, Valle J, Saunders M, Felix R, Soranson JA, Rolfe L, Zinkewich-Peotti K, Jayson GC. Ton NC, et al. Among authors: watson y. Clin Cancer Res. 2007 Dec 1;13(23):7113-8. doi: 10.1158/1078-0432.CCR-07-1550. Clin Cancer Res. 2007. PMID: 18056191 Clinical Trial.
Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging.
O'Connor JP, Carano RA, Clamp AR, Ross J, Ho CC, Jackson A, Parker GJ, Rose CJ, Peale FV, Friesenhahn M, Mitchell CL, Watson Y, Roberts C, Hope L, Cheung S, Reslan HB, Go MA, Pacheco GJ, Wu X, Cao TC, Ross S, Buonaccorsi GA, Davies K, Hasan J, Thornton P, del Puerto O, Ferrara N, van Bruggen N, Jayson GC. O'Connor JP, et al. Among authors: watson y. Clin Cancer Res. 2009 Nov 1;15(21):6674-82. doi: 10.1158/1078-0432.CCR-09-0731. Epub 2009 Oct 27. Clin Cancer Res. 2009. PMID: 19861458 Free PMC article.
A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours.
Horsley L, Cummings J, Middleton M, Ward T, Backen A, Clamp A, Dawson M, Farmer H, Fisher N, Halbert G, Halford S, Harris A, Hasan J, Hogg P, Kumaran G, Little R, Parker GJ, Potter P, Saunders M, Roberts C, Shaw D, Smith N, Smythe J, Taylor A, Turner H, Watson Y, Dive C, Jayson GC; Cancer Research UK Drug Development Office Phase I clinical trial. Horsley L, et al. Among authors: watson y. Cancer Chemother Pharmacol. 2013 Dec;72(6):1343-52. doi: 10.1007/s00280-013-2320-9. Epub 2013 Oct 20. Cancer Chemother Pharmacol. 2013. PMID: 24141375 Clinical Trial.
Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume.
Jayson GC, Parker GJ, Mullamitha S, Valle JW, Saunders M, Broughton L, Lawrance J, Carrington B, Roberts C, Issa B, Buckley DL, Cheung S, Davies K, Watson Y, Zinkewich-Péotti K, Rolfe L, Jackson A. Jayson GC, et al. Among authors: watson y. J Clin Oncol. 2005 Feb 10;23(5):973-81. doi: 10.1200/JCO.2005.01.032. Epub 2004 Oct 4. J Clin Oncol. 2005. PMID: 15466784 Clinical Trial.
Identification of early predictive imaging biomarkers and their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapy.
Mitchell CL, O'Connor JPB, Jackson A, Parker GJM, Roberts C, Watson Y, Cheung S, Davies K, Buonaccorsi GA, Clamp AR, Hasan J, Byrd L, Backen A, Dive C, Jayson GC. Mitchell CL, et al. Among authors: watson y. Ann Oncol. 2010 Oct;21(10):1982-1989. doi: 10.1093/annonc/mdq079. Epub 2010 Mar 29. Ann Oncol. 2010. PMID: 20351070 Free article.
A two-part phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics.
Mitchell CL, O'Connor JP, Roberts C, Watson Y, Jackson A, Cheung S, Evans J, Spicer J, Harris A, Kelly C, Rudman S, Middleton M, Fielding A, Tessier J, Young H, Parker GJ, Jayson GC. Mitchell CL, et al. Among authors: watson y. Cancer Chemother Pharmacol. 2011 Sep;68(3):631-41. doi: 10.1007/s00280-010-1534-3. Epub 2010 Dec 1. Cancer Chemother Pharmacol. 2011. PMID: 21120480 Clinical Trial.
53 results